Olanzapina Kern Pharma (Olanzapine)

Olanzapine is indicated for psychiatric conditions that involve dopamine and serotonin dysregulation.

• Schizophrenia: helps reduce hallucinations, delusions and thought disorder.
• Bipolar I disorder (manic phase): assists in controlling acute manic episodes.
• Bipolar I disorder (maintenance): supports long‑term mood stabilization.
• Schizoaffective disorder: alleviates both psychotic and mood symptoms.
• Psychotic depression: augments antidepressant therapy to improve depressive and psychotic features.

• Olanzapine exerts its antipsychotic effect by antagonizing dopamine D2 receptors and serotonin 5‑HT2A/2C receptors, while also influencing histamine H1, muscarinic and adrenergic receptors. This broad receptor profile reduces dopaminergic overactivity and modulates serotonergic pathways, helping to stabilize mood and diminish psychotic symptoms.

Olanzapine may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Weight gain: increased appetite and caloric intake.
• Sedation: drowsiness or feeling of being unusually tired.
• Dry mouth: reduced salivation.
• Constipation: slowed gastrointestinal motility.
• Elevated triglycerides: rise in blood lipid levels.
• Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability.
• Hyperglycaemia: significant increase in blood glucose, potentially leading to diabetes.
• Tardive dyskinesia: involuntary, repetitive movements, often of the face.
• Seizures: risk of convulsive episodes, especially at higher doses.
• Agranulocytosis: severe reduction in white‑blood cell count.
• Hepatotoxicity: liver enzyme elevations or liver injury.

When prescribing Olanzapine, clinicians should consider several safety aspects.

• Metabolic monitoring: regularly assess weight, fasting glucose and lipid profile.
• Cardiovascular assessment: monitor blood pressure and heart rate, especially during initiation.
• CNS depression: caution patients about operating machinery or driving if drowsiness occurs.
• Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed.
• Drug‑induced movement disorders: watch for early signs of tardive dyskinesia.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olanzapine can interact with a variety of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine plasma levels.
• CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.
• Anticholinergic agents: heightened anticholinergic burden.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce olanzapine concentrations.
• Antihypertensive drugs: potential for enhanced hypotensive effect.
• Lithium: may increase risk of neurotoxic effects.